AMBLYOTECH
Amblyotech is the developer of novel electronic media therapies designed for the treatment of Amblyopia and other ocular diseases and conditions in adults and children. It has developed a revolutionary treatment to cure Amblyopia without the need of current treatment options, including patching, atropine drops, and surgery The company was founded in 2013 and headquartered in Atlanta, Georgia.
AMBLYOTECH
Industry:
Digital Media Electronics Health Care Medical
Founded:
2013-01-01
Address:
Atlanta, Georgia, United States
Country:
United States
Website Url:
http://www.amblyotech.com
Total Employee:
1+
Status:
Closed
Contact:
(770) 366-6229
Email Addresses:
[email protected]
Total Funding:
602.2 K USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail GStatic Google Static Content Twemoji Akamai DNS
Similar Organizations
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Equinox
Equinox is a developer of a medical technology in revolutionizing the treatment of glaucoma and other progressive eye diseases.
Impact Biomedicines
Impact Biomedicines is pioneering the development of life-changing treatments for patients.
Current Employees Featured
Founder
Official Site Inspections
http://www.amblyotech.com
- Host name: 104.18.43.218
- IP address: 104.18.43.218
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Amblyotech"
Amblyotech - Crunchbase Company Profile & Funding
Amblyotech is the developer of novel electronic media therapies designed for the treatment of Amblyopia and other ocular diseases.See details»
Amblyotech 2025 Company Profile: Valuation, …
Information on acquisition, funding, cap tables, investors, and executives for Amblyotech. Use the PitchBook Platform to explore the full profile.See details»
Novartis acquires Amblyotech, pursuing novel digital therapy for ...
Apr 20, 2020 Designed to enhance compliance, Amblyotech utilizes active gaming and passive video technology with 3-D glasses, training the eyes to work together to view an image in full. …See details»
Amblyotech - The Org
Amblyotech is the developer of novel electronic media therapies designed for the treatment of Amblyopia and other ocular diseases and conditions in adults and children. It has developed a …See details»
Amblyotech Company Profile | Management and Employees List
Amblyotech Profile and History Joseph Koziak (CEO) and Robert Derricotte (COO) to develop technologies originally discovered by Dr. Robert Hess. In conjunction with Ubisoft …See details»
Amblyotech Company Profile - Office Locations, Competitors
See insights on Amblyotech including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Amblyotech, A Digital Therapeutics Company, …
Apr 20, 2020 - Amblyotech Inc. is a clinical stage digital therapeutics company committed to the advancement of treatments and diagnostics for amblyopia (lazy eye) and other ocular disorders - Acquisition will ...See details»
Amblyotech - Company Profile - Tracxn
Amblyotech - App to correct Amblyopia. Acquired by Novartis. Raised a total funding of $1.84M over 3 rounds from 1 investor. Founded by Joseph Koziak and Robert Derricotte in the year …See details»
Amblyotech Inc. Company Profile | Phoenix, AZ - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Amblyotech Inc. of Phoenix, AZ. Get the latest business insights from Dun & Bradstreet.See details»
Amblyotech - Ownership and Business Overview | Mergr
Amblyotech, Inc. is a digital therapeutics software company, which develops active and passive video therapies to treat amblyopia ("lazy eye"), a debilitating ocular condition that affects 3% of …See details»
Amblyotech - VentureRadar
As a company that’s part life science and part software development, we are committed to offering revolutionary, first-in-class solutions for treating amblyopia and other ocular disorders. …See details»
Novartis Acquires Lazy Eye Treatment Company Amblyotech
Ambylotech’s approach in treating lazy eye Current treatments for lazy eye include patching and atropine, which are associated with low compliance and low success rates, Novartis said. Five …See details»
Novartis buys Amblyotech to develop tech products for lazy eye
Apr 20, 2020 Novartis <NOVN.S> has bought U.S. software start-up Amblyotech, to develop digital technology to treat children and adults with lazy eye, the Swiss drugmaker said on …See details»
Novartis Acquires Amblyotech as it Pursues Novel Digital Therapy …
Apr 21, 2020 With the transaction closing, Novartis plans to work in partnership with video game developer, Ubisoft, to develop the Amblyotech software as a medical device (SaMD), create a …See details»
Amblyotech | Ophthalmology Innovation Source
Amblyotech CEO Joseph Koziak describes the company as a “hybrid” life science and software company that is refining its tablet-based treatment platform for amblyopia in adolescents and …See details»
Amblyotech Inc. Company Profile | Phoenix, AZ - Dun & Bradstreet
Amblyotech Inc. Company Profile | Phoenix, AZ | Competitors, Financials & Contacts - Dun & BradstreetKey Principal: Joseph Koziak See more contacts Industry: Scientific Research and …See details»
Novartis acquires Amblyotech, a digital therapeutics company
Apr 20, 2020 Novartis, a Swiss drugmaker with U.S. operations in Hanover, has acquired Amblyotech Inc., a Phoenix, Arizona-based clinical stage digital therapeutics company. Once …See details»
Novartis Acquires Amblyotech, A Provider of Digital Therapy for ...
Nov 8, 2019 Novartis announced that it has completed the acquisition of Amblyotech, a US-based software startup, and will, in collaboration with Ubisoft and McGill University, pursue the …See details»
Novartis acquires Amblyotech - mergersight.com
Novartis has acquired Amblyotech, a digital therapeutics company, for an undisclosed amount, with the hopes of developing a modality to combat lazy eye.See details»
Novartis buys Amblyotech to develop digital therapy for lazy eye …
Apr 20, 2020 Novartis has acquired US-based software startup Amblyotech to develop novel digital therapy for children and adult patients with lazy eye.See details»